Physician profile
Donna Ott
NPI 1730124777
$4,293.51
in general payments reported to CMS, 2019-2025
21 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $354 · 2021: $1,026 · 2022: $1,541 · 2023: $365 · 2024: $194 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,140.14 | 2021-2024 | |
| Novo Nordisk INC | $395.82 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $225.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $224.47 | 2022-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $191.86 | 2019-2021 | |
| Amarin Pharma, INC. | $190.71 | 2019-2021 | |
| Pfizer INC. | $188.83 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.97 | 2021 | |
| Aimmune Therapeutics, INC. | $124.99 | 2025 | Zenpep |
| Esperion Therapeutics, INC. | $124.73 | 2021 | |
| Allergan, INC. | $63.06 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $57.25 | 2020-2021 | |
| Glaxosmithkline, LLC. | $52.77 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.51 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.06 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.34 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $24.45 | 2020-2021 | |
| Amgen INC. | $15.53 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.34 | 2019 | |
| Sanofi Pasteur INC. | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.